Samuel Agresta, MD

CMO
Foghorn Therapeutics

Medical Oncologist by training.

Soft tissue and bone sarcoma specialty training.

Experience in solid and liquid tumor drug development.

Worked on the approvals of Tibsovo and IDHHIFA for patients with AML.

CMO of Foghorn for over 3 years

Family of three boys, 2 cats, and a wife.

Enjoy running and hiking.

Poster(s):

• (P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA